To address this gap, we performed a systematic review and meta-analysis of randomized controlled clinical trials (RCTs) evaluating the impact of SGLT2 inhibitors on various arrhythmias, including AF/AFL, ventricular tachycardia (VT), ventricular fibrillation (VF), and sinus bradycardia, with the ultimate goal of informing evidence-based clinical decision-making. This evidence concerns the gene SLC5A2 and ventricular fibrillation.